MX350689B - Proteinas env lentivirales mutadas y su uso como farmacos. - Google Patents
Proteinas env lentivirales mutadas y su uso como farmacos.Info
- Publication number
- MX350689B MX350689B MX2014006744A MX2014006744A MX350689B MX 350689 B MX350689 B MX 350689B MX 2014006744 A MX2014006744 A MX 2014006744A MX 2014006744 A MX2014006744 A MX 2014006744A MX 350689 B MX350689 B MX 350689B
- Authority
- MX
- Mexico
- Prior art keywords
- lentiviral env
- drugs
- mutated lentiviral
- env proteins
- mutated
- Prior art date
Links
- 102100034353 Integrase Human genes 0.000 title abstract 3
- 108010078428 env Gene Products Proteins 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306625 | 2011-12-07 | ||
| PCT/EP2012/074835 WO2013083799A1 (en) | 2011-12-07 | 2012-12-07 | Mutated lentiviral env proteins and their use as drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014006744A MX2014006744A (es) | 2014-12-08 |
| MX350689B true MX350689B (es) | 2017-09-13 |
Family
ID=47435901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006744A MX350689B (es) | 2011-12-07 | 2012-12-07 | Proteinas env lentivirales mutadas y su uso como farmacos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9682137B2 (enExample) |
| EP (1) | EP2788372B1 (enExample) |
| JP (2) | JP6415324B2 (enExample) |
| KR (1) | KR102059918B1 (enExample) |
| CN (1) | CN104169295B (enExample) |
| AU (1) | AU2012350258B2 (enExample) |
| BR (1) | BR112014013704B1 (enExample) |
| CA (1) | CA2856180C (enExample) |
| DK (1) | DK2788372T3 (enExample) |
| ES (1) | ES2748864T3 (enExample) |
| IL (1) | IL232926B (enExample) |
| IN (1) | IN2014CN04927A (enExample) |
| MX (1) | MX350689B (enExample) |
| RU (1) | RU2654673C2 (enExample) |
| WO (1) | WO2013083799A1 (enExample) |
| ZA (1) | ZA201403617B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351247B2 (en) * | 2017-09-01 | 2022-06-07 | Inprother Aps | Vaccine for use in the prophylaxis and/or treatment of a disease |
| CN117500931A (zh) * | 2021-01-13 | 2024-02-02 | 维洛克塞斯 | 麻疹-hiv或麻疹-htlv疫苗 |
| US20240093233A1 (en) | 2021-01-13 | 2024-03-21 | Viroxis | Measles-hiv or measles-htlv vaccine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1201750A1 (en) * | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| WO2005012502A2 (en) | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| AU2005229411B2 (en) * | 2004-03-30 | 2010-11-18 | Centre National De La Recherche Scientifique | Polypeptide sequence involved in the modulation of the immunosuppressive effect of viral proteins |
| EP2420248A1 (en) | 2004-08-17 | 2012-02-22 | Institut Gustave Roussy | Mutated HIV NEF for modulating immunity |
| CA2735278A1 (en) | 2008-08-28 | 2010-03-04 | Aarhus Universitet | Hiv-1 envelope polypeptides for hiv vaccine |
| RU2426788C1 (ru) * | 2010-03-01 | 2011-08-20 | Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ЦНИИЭ Роспотребнадзора) | Генетические конструкции для антивич-терапии |
-
2012
- 2012-12-07 EP EP12806388.0A patent/EP2788372B1/en active Active
- 2012-12-07 BR BR112014013704-8A patent/BR112014013704B1/pt not_active IP Right Cessation
- 2012-12-07 IN IN4927CHN2014 patent/IN2014CN04927A/en unknown
- 2012-12-07 WO PCT/EP2012/074835 patent/WO2013083799A1/en not_active Ceased
- 2012-12-07 CN CN201280060076.2A patent/CN104169295B/zh not_active Expired - Fee Related
- 2012-12-07 AU AU2012350258A patent/AU2012350258B2/en not_active Ceased
- 2012-12-07 KR KR1020147018840A patent/KR102059918B1/ko not_active Expired - Fee Related
- 2012-12-07 US US14/363,095 patent/US9682137B2/en not_active Expired - Fee Related
- 2012-12-07 JP JP2014545294A patent/JP6415324B2/ja not_active Expired - Fee Related
- 2012-12-07 CA CA2856180A patent/CA2856180C/en active Active
- 2012-12-07 MX MX2014006744A patent/MX350689B/es active IP Right Grant
- 2012-12-07 DK DK12806388.0T patent/DK2788372T3/da active
- 2012-12-07 RU RU2014127521A patent/RU2654673C2/ru active
- 2012-12-07 ES ES12806388T patent/ES2748864T3/es active Active
-
2014
- 2014-05-19 ZA ZA2014/03617A patent/ZA201403617B/en unknown
- 2014-06-02 IL IL232926A patent/IL232926B/en active IP Right Grant
-
2018
- 2018-06-04 JP JP2018107061A patent/JP2018150370A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK2788372T3 (da) | 2019-10-14 |
| RU2654673C2 (ru) | 2018-05-21 |
| JP2018150370A (ja) | 2018-09-27 |
| AU2012350258B2 (en) | 2017-03-02 |
| ES2748864T3 (es) | 2020-03-18 |
| RU2014127521A (ru) | 2016-02-10 |
| IN2014CN04927A (enExample) | 2015-09-18 |
| EP2788372A1 (en) | 2014-10-15 |
| EP2788372B1 (en) | 2019-07-10 |
| AU2012350258A8 (en) | 2014-07-17 |
| US9682137B2 (en) | 2017-06-20 |
| IL232926A0 (en) | 2014-07-31 |
| CN104169295B (zh) | 2020-07-28 |
| BR112014013704B1 (pt) | 2023-01-31 |
| CA2856180C (en) | 2022-09-06 |
| MX2014006744A (es) | 2014-12-08 |
| JP2015505836A (ja) | 2015-02-26 |
| KR102059918B1 (ko) | 2020-02-11 |
| BR112014013704A2 (pt) | 2021-02-17 |
| AU2012350258A1 (en) | 2014-06-05 |
| CN104169295A (zh) | 2014-11-26 |
| WO2013083799A1 (en) | 2013-06-13 |
| IL232926B (en) | 2019-01-31 |
| CA2856180A1 (en) | 2013-06-13 |
| ZA201403617B (en) | 2015-07-29 |
| US20140294880A1 (en) | 2014-10-02 |
| JP6415324B2 (ja) | 2018-10-31 |
| KR20140116091A (ko) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012003075A1 (es) | Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion. | |
| CY1121511T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
| NZ630542A (en) | Methods of treating a tauopathy | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| MY168297A (en) | Cytotoxic Peptides and Antibody Drug Conjugates Thereof | |
| EA201290590A1 (ru) | Модифицированные туберкулезные антигены | |
| HUE042360T2 (hu) | Izoxazolin hatóanyagot tartalmazó parazitaellenes készítmények, ezek elõállítása és alkalmazása | |
| MX2013004061A (es) | Analogos de ciclosporina. | |
| GB201106750D0 (en) | Novel compounds | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
| EA201390203A1 (ru) | Способы получения тубулизинов | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| MX2015001083A (es) | Polipeptidos de factor x modificados y usos de los mismos. | |
| EP4302783A3 (en) | Modified relaxin polypeptides and their uses | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| EA201300132A1 (ru) | Фармацевтическая композиция и методы лечения и профилактики заболеваний, вызванных вич или ассоциированных с вич | |
| MX2013004062A (es) | Analogos de ciclosporina. | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| EP2678031A4 (en) | COMBINED VACCINATION WITH CELL-BASED GP96-IG-SIV / HIV AND THE RECOMBINANT PROTEIN GP120 FOR PROTECTION AGAINST SIV / HIV | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| EA201490041A1 (ru) | Пластырь, содержащий диклофенак и тиоколхикозид |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |